

Erratum ▼

DOI: <http://dx.doi.org/10.1590/abd1806-4841.201893405>

In the manuscript "Metabolic syndrome, C-reactive protein and cardiovascular risk in psoriasis patients: a cross-sectional study", with DOI number: 10.1590/abd1806-4841.20186397, published in the Anais Brasileiros de Dermatologia (Brazilian Annals of Dermatology), 2018;93(2):222-8, in the page224.

Where it reads:

TABLE 1: Metabolic syndrome, cardiovascular risk and PASI-defined disease severity parameters according to genders of psoriasis patients

	Overall	Male	Female	P-value
Number, n (%)	90 (100)	45 (50)	45 (50)	
Age (years)	49.0	48.8	49.2	
PASI	12.0	13.6	10.4	
Moderate - Severe PsO (PASI \geq 10), n (%)	50 (55.6)	27 (60.0)	23 (51.1)	0.40
Mild PsO (PASI <10)	40 (44.4)	18 (40.0)	22 (48.9)	
CRP (mean) mg/dL	2.93	2.74	3.11	0.59
Metabolic syndrome (NCEP- ATP III), n (%)	39 (43.3)	16 (35.6)	23 (51.1)	0.14
Obesity (waist circumference > 102 cm for men, > 88 cm for women), n (%)	29 (32.2)	10 (22.2)	19 (42.2)	0.04
Triglycerides (\geq 150 mg/dL), n (%)	35 (38.9)	15 (33.3)	20 (44.4)	0.28
HDL- cholesterol (<40 mg/dL in men, <50 mg/dL in women), n (%)	43 (47.8)	26 (57.8)	17 (37.8)	0.27
Systemic arterial hypertension (\geq 130/ \geq 85 mmHg), n (%)	45 (50)	17 (35.6)	29 (64.4)	0.006
Fasting glucose (\geq 110 mg/dL), n (%)	28 (31.1)	14 (31.1)	14 (31.1)	1.00
Cardiovascular risk (absolute %)	8.7	11.5	5.9	0.002
\geq 20%, n (%)	3 (3.3)	3 (6.6)	0	
10% \geq CVR < 20%, n (%)	29 (32.2)	19 (42.2)	10 (22.2)	
< 10%, n (%)	58 (64.4)	23 (51.1)	35 (77.8)	
Cardiovascular risk (global assessment)				
High-Intermediate, n (%)	46 (51.1)	22 (48.9)	24 (53.3)	0.83
Low, n (%)	44 (43.3)	23 (51.1)	21 (35.6)	

PsO, Psoriasis; PASI, Psoriasis Area and Severity Index; CRP, C-reactive protein; NCEP-ATP III, National Cholesterol Education Program - Adult Treatment Panel III; HDL, high-density lipoprotein.

It should read

TABLE 1: Metabolic syndrome, cardiovascular risk and PASI-defined disease severity parameters according to genders of psoriasis patients

	Overall	Male	Female	P-value
Number, n (%)	90 (100)	45 (50)	45 (50)	
Age (years)	49.0	48.8	49.2	
PASI	12.0	13.6	10.4	
Moderate - Severe PsO (PASI \geq 10), n (%)	50 (55.6)	27 (60.0)	23 (51.1)	0.40
Mild PsO (PASI <10)	40 (44.4)	18 (40.0)	22 (48.9)	
CRP (mean) mg/dL	2.93	2.74	3.11	0.59
Metabolic syndrome (NCEP- ATP III), n (%)	39 (43.3)	16 (35.6)	23 (51.1)	0.14
Obesity (waist circumference > 102 cm for men, > 88 cm for women), n (%)	29 (32.2)	10 (22.2)	19 (42.2)	0.04
Triglycerides (\geq 150 mg/dL), n (%)	35 (38.9)	15 (33.3)	20 (44.4)	0.28
HDL- cholesterol (<40 mg/dL in men, <50 mg/dL in women), n (%)	43 (47.8)	26 (57.8)	17 (37.8)	0.27
Systemic arterial hypertension (\geq 130/ \geq 85 mmHg), n (%)	45 (50)	17 (35.6)	29 (64.4)	0.006
Fasting glucose (\geq 110 mg/dL), n (%)	28 (31.1)	14 (31.1)	14 (31.1)	1.00
Cardiovascular risk (absolute %)	8.7	11.5	5.9	0.002
\geq 20%, n (%)	3 (3.3)	3 (6.6)	0	
$10\% \leq$ CVR < 20%, n (%)	29 (32.2)	19 (42.2)	10 (22.2)	
< 10%, n (%)	58 (64.4)	23 (51.1)	35 (77.8)	
Cardiovascular risk (<i>global assessment</i>)				
High-Intermediate, n (%)	46 (51.1)	22 (48.9)	24 (53.3)	0.83
Low, n (%)	44 (43.3)	23 (51.1)	21 (35.6)	

PsO, Psoriasis; PASI, Psoriasis Area and Severity Index; CRP, C-reactive protein; NCEP-ATP III, National Cholesterol Education Program - Adult Treatment Panel III; HDL, high-density lipoprotein.